Englewood Health’s cardiothoracic surgery team is now incorporating the Inspiris valve into its decision-making process when evaluating patients preoperatively.

Edwards Lifesciences Corporation (EW) recently announced the receipt of FDA approval for its INSPIRIS RESILIA aortic valve.

Edwards Lifesciences announced new data from the COMMENCE aortic trial, demonstrating low rates of structural valve deterioration (SVD) in bioprosthet ...

Edwards’ INSPIRIS RESILIA and SAPIEN 3 Ultra RESILIA valves are supported by extensive, long-term clinical evidence which is the result of three decades of innovation and expertise, leveraging ...

The company’s most recent breakthrough, the Inspiris Resilia aortic valve, is constructed on the Perimount platform and features Resilia tissue and VFit technology.

“Given that TAVR is mounted on a flexible stent, unlike Inspiris with Resilia tissue mounted on a rigid surgical valve frame, we will need to determine the long-term outcomes of Resilia in a ...

It also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology ...

The valve known as the Inspiris Resilia Aortic Valve was implanted by a team led by Dr. Isaac Okyere from the Department of Surgery. The aortic valve controls the flow of blood between the left ...

CAIRO, April 18, 2025--Edwards Lifesciences (NYSE: EW) today announced new eight-year data showing that patients receiving aortic surgical valves treated with its proprietary RESILIA tissue ...

Edwards Lifesciences announced new data from the COMMENCE aortic trial, demonstrating low rates of structural valve deterioration (SVD) in bioprosthetic aortic valves with the company's innovative ...

Edwards’ INSPIRIS RESILIA and SAPIEN 3 Ultra RESILIA valves are supported by extensive, long-term clinical evidence which is the result of three decades of innovation and expertise, leveraging ...